Tag Archives: Gilead

The Market Will Demand a Cheaper Alternative to Sovaldi

A new report from Frost & Sullivan forecasts “robust demand” for HCV antivirals, with several strong competitors “maneuvering aggressively” to narrow the market gap by introducing a treatment that can outdo Gilead’s Sovaldi.
Posted in healthcare, pricing, Strategy | Also tagged , , | Leave a comment

Paying for the Future of Medicine

Is the hallmark of innovation higher drug prices? The three leading justifications for sticker-shocking drug prices in the US, from the biopharma perspective, are: 1) it costs a lot to bring a drug to market;* 2) drugs – even very expensive ones – are cheaper in the long run since they prevent complications, hospitalizations and […]
Posted in Biotech, FDA, healthcare, leadership, Manufacturing, Market Access, pricing, R&D, Regulatory, Technology | Also tagged , , , , , | 1 Comment

Sovaldi “Biggest Selling Drug” by 2020

Gilead’s hepatitis C treatment Sovaldi will top the list of biggest selling drugs in 2020, according to UK market intelligence company, Evaluate. “Given its history-making launch, it is no surprise that [Sovaldi] is forecast to become the biggest drug in 2020; the big question will be how long this drug can hang onto the top spot,” […]
Posted in Europe, Gene therapy, Global, Sales, Strategy | Also tagged , , , , , , | Leave a comment

High Price of Gilead's Sovaldi Could Deter Early Hep C Treatment

Gilead Silences has cleaned up on their new $1,000 Hepatitis C pill Sovaldi (84,000 per treatment), hauling in a record-breaking $2.3 billion in its first full quarter on the market. The previous record (also a Hepatitis C drug Incivek from Vertex) came in with $1.56 billion, according to EP Vantage. And Sovaldi may well go […]
Posted in healthcare, pricing | Also tagged , | 1 Comment

Is Gilead’s $1000 Pill Worth It?

The Department of Veterans Affairs and other California panels’ solution to the new and extremely costly hepatitis (Hep) C drugs (Sovaldi and Olysio) is to reserve them for the patients with advanced liver diseases, including those awaiting transplants. What should the patients of “milder” cases do then? Twiddle their thumbs and wait for drugs in […]
Posted in pricing, Regulatory | Also tagged , , , | 2 Comments
  • Categories

  • Meta